Safety perspectives on presently considered drugs for the treatment of COVID‐19

Collapse authors list.
Penman, Sophie L ORCID: 0000-0001-5326-1675, Kiy, Robyn T ORCID: 0000-0001-7960-7283, Jensen, Rebecca L ORCID: 0000-0003-1134-2869, Beoku‐Betts, Christopher, Alfirevic, Ana ORCID: 0000-0002-2801-9817, Back, David, Khoo, Saye H, Owen, Andrew ORCID: 0000-0002-9819-7651, Pirmohamed, Munir ORCID: 0000-0002-7534-7266, Park, B Kevin ORCID: 0000-0001-8384-824X et al (show 3 more authors) , Meng, Xiaoli ORCID: 0000-0002-7774-2075, Goldring, Christopher E and Chadwick, Amy E ORCID: 0000-0002-7399-8655 (2020) Safety perspectives on presently considered drugs for the treatment of COVID‐19. British Journal of Pharmacology, 177 (19). pp. 4353-4374.

Access the full-text of this item by clicking on the Open Access link.

Text Safety perspectives on presently considered drugs for the treatment of COVID-19.pdf - Published version Download (5MB) | Preview

Abstract

Intense efforts are underway to evaluate potential therapeutic agents for the treatment of COVID‐19. In order to respond quickly to the crisis, the repurposing of existing drugs is the primary pharmacological strategy. Despite the urgent clinical need for these therapies, it is imperative to consider potential safety issues. This is important due to the harm–benefit ratios that may be encountered when treating COVID‐19, which can depend on the stage of the disease, when therapy is administered and underlying clinical factors in individual patients. Treatments are currently being trialled for a range of scenarios from prophylaxis (where benefit must greatly exceed risk) to severe life‐threatening disease (where a degree of potential risk may be tolerated if it is exceeded by the potential benefit). In this perspective, we have reviewed some of the most widely researched repurposed agents in order to identify potential safety considerations using existing information in the context of COVID‐19.

Item Type:	Article
Uncontrolled Keywords:	COVID-19, drug repurposing, drug safety, toxicology
Depositing User:	Symplectic Admin
Date Deposited:	12 Oct 2020 15:04
Last Modified:	18 Jan 2023 23:29
DOI:	10.1111/bph.15204
Open Access URL:	https://bpspubs.onlinelibrary.wiley.com/doi/epdf/1...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3104050

Available Versions of this Item

• Safety perspectives on presently considered drugs for the treatment of COVID‐19. (deposited 29 Jul 2020 13:39)
  • Safety perspectives on presently considered drugs for the treatment of COVID‐19. (deposited 12 Oct 2020 15:04) [Currently Displayed]